Skip to main content
. 2021 May 24;8:687149. doi: 10.3389/fmed.2021.687149

Table 3.

Baseline characteristics of patients with MG with kidney injury who underwent a kidney biopsy.

Characteristic Kidney biopsy not relevant with malignant neoplasms (n = 85) MGRS-related lesions (n = 43) MG-unrelated lesions (n = 42) P
Male 60 (70.6%) 26 (60.5%) 34 (81.0%) 0.038
Age (year) 55.8 ± 12.4 57.7 ± 11.0 53.9 ± 13.6 0.161
Hypertension 32 (37.6%) 12 (27.9%) 20 (47.6%) 0.061
Diabetes 15 (17.6%) 4 (9.3%) 11 (26.2%) 0.041
Hepatitis B 7 (8.2%) 3 (7.0%) 4 (9.5%) 0.669
Serum studies
Albumin (g/l) 24.9 ± 8.2 23.6 ± 8.3 26.2 ± 8.0 0.139
Creatinine (μmo/l) 160.1 ± 155.9 166.4 ± 175.3 153.5 ± 135.0 0.705
eGFR (ml/min per 1.73 m2) 63.7 ± 33.9 60.0 ± 33.3 67.5 ± 34.5 0.309
eGFR <60 (ml/min per 1.73 m2) 39 (45.9%) 24 (55.8%) 15 (35.7%) 0.063
κ/λ 1.35 (0.73–1.91) 0.78 (0.51–1.70) 1.60 (1.26–2.25) 0.57
Urinary studies
Urinary protein (g/d) 5.64 (2.03–7.07) 5.91 (3.57–7.21) 3.37 (1.59–7.96) 0.44
Proteinuria >1.5 g/d 32 (82.1%) 18 (85.7%) 14 (77.8%) 0.52
Hematuria 60 (70.6%) 30 (69.8%) 30 (71.4%) 0.867
κ/λ 1.36 (0.53–2.2) 0.69 (0.21–1.42) 1.98 (1.47–3.77) 0.478
Hematologic studies
Clonal subtype
Ig isotype
IgA(+) 15 (17.6%) 7 (16.3%) 8 (19.0%) 0.738
IgG(+) 24 (28.2%) 13 (30.2%) 11 (26.2%) 0.679
IgM(+) 10 (11.8%) 3 (7.0%) 7 (16.7%) 0.166
IgA/IgG/IgM(+) 0 (0) 0 (0) 0 (0) /
IgA&IgG&IgM(−) 36 (42.4%) 20 (46.5%) 16 (38.1%) 0.432
Ig light chain
Kappa(+) 21 (24.7%) 7 (16.3%) 14 (33.3%) 0.068
Lambda(+) 51 (60.0%) 29 (67.4%) 22 (52.4%) 0.156
Kappa&Lambda(+) 0 (0) 0 (0) 0 (0) /
Kappa&Lambda(−) 13 (15.3%) 7 (16.3%) 6 (14.3%) 0.799
Received BM biopsy 49 (57.6%) 27 (62.8%) 22 (52.4%) 0.332

Values for continuous variables are described as mean ± SD or median (IQR) depending on the distribution, and for categoric variables described as count (%).